NYSTATIN- nystatin suspension
ATLANTIC BIOLOGICALS CORP.

NYSTATIN ORAL SUSPENSION, USP

DESCRIPTION

Nystatin is obtained from *Streptomyces noursei.* It is known to be a mixture, but the composition has not been completely elucidated. Nystatin A is closely related to amphotericin B. Each is a macro-cyclic lactone containing a ketal ring, an *all-trans* polyene system, and a mycosamine (3-amino-3-deoxyrhamose) moiety.
Structural formula:



$C_{47}H_{75}NO_{17}$ MW 926.13

Nystatin Oral Suspension, for oral administration, contains 100,000 USP Nystatin Units per mL. Inactive ingredients: alcohol (≤ 1% v/v), sucrose 50% w/v, peppermint oil, NF, cinnamaldehyde, disodium hydrogen phosphate, USP, carboxymethylcellulose sodium, USP, glycerin, USP, saccharin sodium, USP, cherry flavor, methylparaben, NF, propylparaben, NF and purified water, USP. May also contain sodium hydroxide, NF and/or hydrochloric acid, NF for pH adjustment.

CLINICAL PHARMACOLOGY

Nystatin acts by binding to sterols in the cell membrane of the fungus with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin is absorbed very sparingly following oral administration, with no detectable blood levels when given in the recommended doses.

INDICATIONS AND USAGE

Nystatin oral suspension is indicated for the treatment of infections of the oral cavity caused by Candida albicans.

CONTRAINDICATIONS

Nystatin is contraindicated in patients with a history of hypersensitivity to nystatin or any of the suspension components.

PRECAUTIONS

General
Discontinue treatment with nystatin if sensitization or irritation is reported during use. Nystatin is not effective in the treatment of systemic mycoses since it is not significantly absorbed from the gastrointestinal
tract.

Information for the Patient
Patient should be advised to retain nystatin in the mouth as long as possible and to continue its use for at least 2 days after symptoms have subsided.

There should be no interruption or discontinuation of the medication until the prescribed course of treatment is completed, even though symptomatic relief may occur within a few days.
If symptoms of local irritation develop, the physician should be notified immediately.

Laboratory Tests
If there is a lack of therapeutic response, appropriate microbiological studies (e .g., KOH smears and/or cultures) should be repeated to confirm the diagnosis of candidiasis and rule out other pathogens before instituting another course of therapy.

Carcinogenesis, Mutagenesis, Impairment of Fertility
No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin. In mice exposed to nystatin 50 mg/kg by injection, an increased incidence of chromosomal aberrations, consisting primarily of chromatid breaks, was observed in bone marrow cells. However, there have been no studies to determine the mutagenicity of orally-administered nystatin or its effects on fertility in males or females.

Pregnancy:

Teratogenic Effects
Teratogenicity studies have not been conducted with nystatin. It is also not known whether nystatin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin should be given to a pregnant woman only if clearly needed.

Nonteratogenic Effects
In one rat reproductive study, nystatin was administered orally to pregnant rats in single doses of 100, 500, or 3000 mg/kg on the ninth day of gestation, or as multiple doses of 500 mg/kg/day on gestation days 1-20, 1-4, 7-10, 11-14, or 15-18. It was found that nystatin had a slight abortive effect when used during the whole period of pregnancy. No abnormalities were seen in surviving fetuses. Although no adverse effects or complications have been attributed to the use of intra-vaginal nystatin in neonates born to women treated during pregnancy, no similar studies evaluating complications of oral nystatin have been conducted.

Nursing Mothers
It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

Pediatric Use
See **DOSAGE AND ADMINISTRATION**section for pediatric dosing recommendations.

ADVERSE REACTIONS

To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or *www.fda.gov/medwatch.*

Gastrointestinal symptoms including diarrhea, gastrointestinal distress, nausea, vomiting and burning of the mouth have been reported. Hypersensitivity reactions including rash, pruritus, and anaphylactoid reaction have also been reported.

OVERDOSAGE

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset.

DOSAGE AND ADMINISTRATION

Infants: 2 mL (200,000 units) four times daily (1 mL in each side of mouth).

Pediatric patients and adults: 4 to 6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth).

NOTE: Limited clinical studies in neonates, including premature and low-birth weight neonates, indicate that 1 mL (100,000 units) four times daily is effective.

Local treatment should be continued at least 48 hours after perioral symptoms have disappeared and/or cultures returned to normal. It is recommended that the drug be retained in the mouth as long as possible before swallowing.

CAUTION

The Packaging of This Product Contains Natural Rubber Latex Which May Cause Allergic Reactions

HOW SUPPLIED

Nystatin Oral Suspension, USP, 100,000 USP Nystatin Units per mL, is available as a cherry-mint flavored, light creamy yellow, ready-to-use suspension, in the following sizes:

NDC 17856-0508-01 NYSTATIN ORAL SUSP 100,000 UNITS/1ML - 5 ML CUP 72 ct UD

Storage
This package is child-resistant. Keep out of reach of children. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid freezing

Rx Only

Manufactured by:

Medley Pharmaceuticals Ltd.

Plot No. 18 and 19, Survey No. 378 / 7 & 8, 379 / 2 & 3,

Zari Causeway Road, Kachigam, Daman - 396210, INDIA.

Distributed by:

ATLANTIC BIOLOGICALS CORP

MIAMI, FL 33179



17856-0508-03

NYSTATIN
ORAL SUSPENSION, USP
100,000 UNITS PER 1 mL
DELIVERS
500,000 UNITS/5mL

See package insert for indications and dosage schedule

Contains: Alcohol ≤ 1% v/v. Shake Well Before Using. Cherry-Mint Flavored. Avoid Freezing. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Keep this and all Medications out of the reach of children

217856050803

17856-0508-03 **Dosage :** **500,000 UNITS/5mL**

NYSTATIN ORAL SUSPENSION, USP

Qty: 48 SYRINGES

GTIN: 00117856050834
S/N: XXXXXXXXXXX
Exp: 07/17/24
Lot: XXXXXXXXXX

RX

Packaged by:

Distributed by: Atlantic Biologicals Corp.
Miami, FL 33179

Rev.08/21

Call to Reorder:



NYSTATIN

nystatin suspension

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	**Item Code (Source)**	NDC:17856-0508(NDC:69315-504)
Route of Administration	ORAL		

Active Ingredient/Active Moiety		
Ingredient Name	**Basis of Strength**	**Strength**
NYSTATIN (UNII: BDF1O1C72E) (NYSTATIN - UNII:BDF1O1C72E)	NYSTATIN	100000 [USP'U] in 1 mL

Inactive Ingredients

Ingredient Name	Strength
ALCOHOL (UNII: 3K9958V90M)	
SUCROSE (UNII: C151H8M554)	
PEPPERMINT OIL (UNII: AV092KU4JH)	
CINNAMALDEHYDE (UNII: SR60A3XG0F)	
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS (UNII: 22ADO53M6F)	
CARBOXYMETHYLCELLULOSE SODIUM (UNII: K679OBS311)	
GLYCERIN (UNII: PDC6A3C0OX)	
SACCHARIN SODIUM (UNII: SB8ZUX40TY)	
METHYLPARABEN (UNII: A2I8C7HI9T)	
PROPYLPARABEN (UNII: Z8IX2SC1OH)	
WATER (UNII: 059QF0KO0R)	
SODIUM HYDROXIDE (UNII: 55X04QC32I)	
HYDROCHLORIC ACID (UNII: QTT17582CB)	

Product Characteristics

Color	yellow (light creamy yellow)	**Score**	
Shape		**Size**	
Flavor	CHERRY (cherry-mint flavored)	**Imprint Code**	
Contains			

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:17856-0508-1	72 in 1 BOX, UNIT-DOSE	07/15/2024	
1		5 mL in 1 CUP, UNIT-DOSE; Type 0: Not a Combination Product		
2	NDC:17856-0508-3	48 in 1 BOX, UNIT-DOSE	07/17/2024	
2		5 mL in 1 SYRINGE; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)		
3	NDC:17856-0508-5	48 in 1 BOX, UNIT-DOSE	07/17/2024	
3		5 mL in 1 SYRINGE; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)		
4	NDC:17856-0508-7	120 in 1 BOX, UNIT-DOSE	07/17/2024	
4		1 mL in 1 SYRINGE; Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA214346	12/05/2022	

Labeler - ATLANTIC BIOLOGICALS CORP. (047437707)

Revised: 1/2026 ATLANTIC BIOLOGICALS CORP.